1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1)
Gastroesophageal Reflux Disease
Explore 1 assets in Gastroesophageal Reflux Disease →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Nantes University Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Reflux Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) (this asset) | Nantes University Hospital | P2 | B · 57 |
| Pantoprazole | Children's Mercy Hospital Kansas City | P4 | BB |
| Lansoprazole | Children's Mercy Hospital Kansas City | P4 | BB |
| Midazolam | Children's Mercy Hospital Kansas City | P4 | BB |
| Dexlansoprazole | National Cheng-Kung University Hospital | P4 | BB |
| Lidocaine | Hospital Infantil Cândido Fontoura | P3 | BB |
| Tannic Acid | Hospital Infantil Cândido Fontoura | P3 | BB |
| Lactose | Nantes University Hospital | P2 | B |
| Omeprazole | Nantes University Hospital | P2 | B |
+9 more in the Gastroesophageal Reflux Disease cohort
Other indications for 1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P1/2 | CCC · 55 |
| Lymphoma | — | P1 | CCC · 52 |
| Amyotrophic Lateral Sclerosis | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) in Gastroesophageal Reflux Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/1h-benzimidazole-2-4-3-methoxypropoxy-3-methyl-2-pyridinylmethylsulfinyl-sodium-salt-hydrate-111-gastroesophageal-reflux-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →